MP looked promising in Phase I, with a manageable safety profile, which led London-based AstraZeneca to make the compound one of three cancer drugs moving into Phase III trials soon

Development of Tokai Pharmaceuticals Inc.'s triple-acting prostate cancer drug galeterone got a $35.5 million boost, with the Cambridge, Mass.-based biotech closing a Series E round with current investors Apple Tree Partners and Novartis Venture Funds, as well as undisclosed angel investors...ARMOR2, the second study in Tokai's ARMOR (Androgen Receptor Modulation Optimized for Response) program, is testing a new oral formulation of galeterone in CRPC patients, including those with either metastatic

Inc., of Whitehouse Station, N.J. (See BioWorld Today, Feb. 3, 2012.) In all, pharmaceutical companies collectively jettisoned 150,000 jobs worldwide over the past three years, according to a report earlier this year by PwC's Health Research Institute. (See BioWorld Today, Feb. 8, 2013.) Founded in 1983 as Oncogene Science Inc., OSI developed cancer drug Tarceva (erlotinib) in partnership with Genentech Inc., now a unit of Roche AG, of Basel, Switzerland

In its pipeline is cancer drug EC145 (vintafolide), which delivers a potent vinca chemotherapy directly to cancer cells by targeting the folate receptor expressed on cancer cells, but not on most normal cells

That experience should help Array as it develops its own cancer drugs

Patients don't benefit from this type of approach." – Carlo Toniatti, head of research at the Institute for Applied Cancer Science and the Center for Co-Clinical Trials at the University of Texas MD Anderson Cancer Center, discussing improved clinical success rates for cancer drugs identified by the Tufts Center for the Study of Drug Development "It's been a long time since we did a public financing – 12 or 13 years – and we've managed through by being cautious in how we spend our cash and by

The findings appeared in the May 8, 2013, issue of Cell Metabolism. (See BioWorld Today, March 27, 2013.) Cancer Drug Fights Neurodegeneration Very low doses of chronic myelogenous leukemia (CML) drug Tasigna (nilotinib, Novartis AG) may be a way to treat neurodegenerative disorders that are characterized by toxic protein accumulations, scientists from Georgetown University have discovered

Tolcher has been involved in running Phase I studies for a number of marketed cancer drugs, including the recently approved antibody-drug conjugate Kadcyla (trastuzumab emtansine, Roche AG), and Drejer said his appointment "brings a wealth of cancer knowledge to the company."

Ariad Pharmaceuticals Inc., of Cambridge, Mass., reported its first revenue from cancer drug Iclusig (ponatinib), which was approved in December for use in adults with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia that is resistant or intolerant to prior tyrosine kinase inhibitor therapy

Success rates doubled for cancer drugs that entered clinical trials in the early 1990s and those that entered the clinic a decade later, even as the number of such compounds increased by 50 percent over the period, according to a new analysis by the Tufts Center for the Study of Drug Development (CSDD...However, cancer drugs that filed for regulatory approval mostly succeeded, with 92 percent that submitted a new drug application or biologics license application gaining the FDA's endorsement

with its cancer drug EC145 (vintafolide) attracting a potential $1 billion based on the achievement of development, regulatory and commercialization goals for EC145 in six cancer indications. (See BioWorld Today, April 17, 2012.) The upfront $120 million was notable because it represented one of the largest upfront payments to a U.S biotechnology company in 2012, bucking a trend that had seen these payments decline in value during the past five years

BIO said it shares many of the USTR's concerns over the decision by India's Supreme Court to deny patent protection for for the cancer drug Gleevec/Glivec, developed by Novartis AG, of Basel, Switzerland, on the grounds that the compound did not demonstrate "enhanced efficacy

with its cancer drug EC145 (vintafolide) attracting a potential $1 billion based on the achievement of development, regulatory and commercialization goals for EC145 in six cancer indications. (See BioWorld Today, April 17, 2012.) The upfront $120 million was notable because it represented one of the largest upfront payments to a U.S biotechnology company in 2012, bucking a trend that had seen these payments decline in value during the past five years

Allergan licensed rights to the Darpin technology from Molecular Partners AG for development in AMD and other eye diseases. (See BioWorld Today, Aug. 22, 2012.) And Eylea has fared well so far against Roche AG's Lucentis (ranibizumab), due to its lower cost and a label that calls for less frequent dosing, and even to cancer drug Avastin (bevacizumab), a cheaper, off-label alternative

AVEO's confidence in the drug was shared by RBC Capital Markets analyst Adnan Butt, who said he believes tivozanib "could be a differentiated agent that could demonstrate better efficacy than existing kidney cancer drugs...patients, due to differences in standard of care and access to other cancer drugs

Cancer is 50 percent of the market, and so you have to always be looking at cancer drugs," Düster said...One of our earlier investments, which is undisclosed, is in a leading cancer drug, so it's an area of expertise for us and an area of interest to us

Tolcher has been involved in running Phase I studies for a number of marketed cancer drugs, including the recently approved antibody-drug conjugate Kadcyla (trastuzumab emtansine, Roche AG), and Drejer said his appointment "brings a wealth of cancer knowledge to the company

Cancer drug pricing seems to follow a fairly basic formula, however, with new drugs being priced about 10 percent to 20 percent higher than the most recent similar drug on the market...Although much of the discussion is happening outside the U.S., it's not unreasonable to assume that pushback on cancer drug pricing will gain momentum within the U.S

Inhibiting nucleolin in cells that are resistant to the breast cancer drug Faslodex (fulvestrant, AstraZeneca plc) restored sensitivity to the drug both in cell culture and in animal studies